Drug Profile
CAP 1002
Alternative Names: Allogeneic adult stem cell therapy for myocardial infarction - Capricor; Allogeneic cardiosphere-derived cells - Capricor; Allogeneic CDCs - Capricor; Allogenic derived cells - Capricor; CAP-1002Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Capricor
- Developer Capricor; Capricor Therapeutics; Medical University of South Carolina
- Class Exosome therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Duchenne muscular dystrophy
Highest Development Phases
- Phase III Duchenne muscular dystrophy
- Phase II COVID 2019 infections
- Phase I/II Cardiomyopathies
- Discontinued Heart failure; Myocardial infarction
Most Recent Events
- 14 Nov 2023 Capricor plans a meeting with the US FDA in the scheduled for late March of 2024.
- 10 Oct 2023 Updated efficacy data from the phase II HOPE-2-OLE trial in Duchenne Muscular Dystrophy released by Capricor Therapeutics
- 29 Sep 2023 Capricor Therapeutics plans a follow-up Type B meeting with the US FDA to discuss proposed path towards submission of a potential BLA of CAP 1002 and further discuss its ongoing HOPE-3 clinical trial for Duchenne muscular dystrophy, in early 2023